1. 1. UNAIDS. Global HIV & AIDS statistics-Fact sheet. https://www.unaids.org/en/resources/fact-sheet (accessed July 20, 2021).
2. 2. Nolan D, Mallal S. Complications associated with NRTI therapy: Update on clinical features and possible pathogenic mechanisms. Antivir Ther. 2004; 9:849-863.
3. 3. Canadian Agency for Drugs and Technologies in Health. Clinical Review Report: Dolutegravir/Lamivudine (Dovato): (ViiV Healthcare ULC): Indication: As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg. https://pubmed.ncbi.nlm.nih.gov/31877000/ (accessed July 20, 2021).
4. 4. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008; 358:2095-2106.
5. 5. Back D. 2-Drug regimens in HIV treatment: Pharmacological considerations. Germs. 2017; 7:113-114.